Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs Standard of Care in Type 2 Diabetes
NCT03596450Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2018
- Primary completion
- Jun 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jul 2018; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03596450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596450.